Table 2.
Recommended therapies and their durations depending on the viral genotype in adult patients. Detailed information on the therapies and therapeutic management in children are included in the text. The options recommended as first-line therapies are underlined
| GT1a | GT1b | GT2 | GT3 | GT4 | GT5 | GT6 | |
|---|---|---|---|---|---|---|---|
| OBV/PTV/r + DSV + RBV | 12-24 weeks | ||||||
| OBV/PTV/r + DSV | 12 weeks | ||||||
| OBV/PTV/r + RBV | 12-24 weeks | ||||||
| ASV + DCV | 24 weeks | ||||||
| SOF/LDV ± RBV | 12-24 weeks | 12-24 weeks | 24 weeks | 12-24 weeks | 12-24 weeks | 12-24 weeks | |
| SOF + PegIFNα + RBV | 12 weeks | 12 weeks | 12 weeks | 12 weeks | |||
| SOF + RBV | 12-24 weeks | 24 weeks | 24 weeks | 24 weeks | 24 weeks | ||
| SOF + DCV + RBV | 24 weeks | 24 weeks | |||||
| GZR/EBR | 12-16 weeks | 12 weeks | 12 weeks* | 12-16 weeks | |||
| PegIFNα + RBV | 48 weeks** | 48 weeks** | 24 weeks*** | 24 weeks*** | 48 weeks** |
In combination with SOF
Only recommended in children
Recommended in children, in adults subject to consideration
„+” Combined therapy with drugs available as separate preparations
„/” Combined therapy with drugs available as one combined preparation
„±” Addition of RBV depending on indications; details are provided in the text
OBV – ombitasvir, PTV – paritaprevir, /r/ – ritonavir, DSV – dasabuvir, RBV – ribavirin, ASV – asunaprevir, DCV – daclatasvir, SOF – sofosbuvir, PegIFNα – pegylated interferon α, GZR – grazoprevir, EBR – elbasvir